Eli Lilly and Co
Novo Nordisk and Eli Lilly tumble after Hims & Hers announce $49 copy of Wegovy pill
Weight-loss drugmakers Eli Lilly and Novo Nordisk tumbled after telehealth company Hims & Hers announced Thursday it will offer a copy of the newly launched Wegovy pill for $49, far less than the $149 Novo sells the branded pill for. Copenhagen-listed shares of Novo dropped as much as 9% on the news, while Eli Lilly […]
Read More
Jim Cramer says the tech sell-off proves why this old investing rule still matters
The action on Wall Street this week is a reminder of the importance of portfolio diversification, CNBC’s Jim Cramer said Wednesday, as tech-only portfolios have been getting beaten down during the bout of volatility. “Tech’s a good part of the market, it’s just that many of these stocks suddenly aren’t worth as much as we […]
Read More
Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters It’s a tale of two drugmakers in the red-hot obesity drug market. Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline, […]
Read More
Jim Cramer says the software sell-off creates opportunities in stocks outside of tech
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. 1. Stocks were attempting to shake off continued fears that AI disruption could undermine traditional enterprise software companies. Some of the high-multiple names hit hardest in recent sessions, including Club […]
Read More
Disney’s next CEO, Chipotle’s traffic problem, government shutdown ends and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Wednesday. In addition to Disney’s Josh D’Amaro, there was another top dog announced yesterday: Penny the Doberman pinscher won best in show at the Westminster Kennel Club Dog Show. Stock futures are ticking higher this morning. The market is coming off […]
Read More
Stocks making the biggest moves premarket: AMD, Uber, Eli Lilly, Super Micro, Chipotle, Enphase and more
Check out the companies making headlines before the bell. Super Micro Computer — Shares jumped 10% as strong demand for Super Micro’s AI-optimized servers helped fiscal second-quarter results top expectations and prompted the company to raise its annual revenue forecast. Super Micro earned 69 cents per share on an adjusted basis, soundly outpacing the second-quarter […]
Read More
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The pharmaceutical giant […]
Read More
Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better
Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise pre-released its 2026 forecast late Tuesday, sending shares tumbling. Novo Nordisk’s stock plummeted 18% in Copenhagen early Wednesday, tracking losses seen in its American depositary shares on Tuesday and more than wiping out gains seen so far […]
Read More
Novo Nordisk shares tumble after company forecasts sales declines this year
Novo Nordisk‘s U.S. shares plummeted Tuesday after the company said it sees sales and profit growth declining this year, hit by lower prices in the U.S. and loss of exclusivity for its blockbuster Wegovy and Ozempic in China, Brazil and Canada. The company published the forecast as it reported full-year 2025 sales, ahead of the […]
Read More
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in […]
Read More